Buspirone modulates basal and fluoxetine-stimulated dialysate levels of dopamine, noradrenaline and serotonin in the frontal cortex of freely moving rats:: Activation of serotonin1A receptors and blockade of α2-adrenergic receptors underlie its actions

The serotonin(1A) receptor partial agonist, buspirone, also displays antagonist properties at D-2 receptors and is metabolized to the alpha(2)-adrenergic receptor antagonist, 1-(2-pyrimidinyl-piperazine). Herein, we examined mechanisms underlying the influence of buspirone alone, and in association with the serotonin reuptake inhibitor, fluoxetine, upon extracellular levels of serotonin, dopamine and noradrenaline simultaneously quantified in the frontal cortex of freely moving rats. Buspirone (0.01-2.5 mg/kg, s.c.) dose-dependently decreased dialysate levels of serotonin (- 50%), and increased those of dopamine (+ 100%) and noradrenaline (+ 140%). The reduction by buspirone of serotonin levels was abolished by the serotonin(1A) receptor antagonist, WAY 100,635 (0.16), which did not, however, modify its influence upon dopamine and noradrenaline. In contrast to buspirone, the serotonin reuptake inhibitor, fluoxetine (10.0), increased frontocortical levels of serotonin (+ 120%), dopamine (+ 55%) and noradrenaline (+ 90%). Buspirone dose-dependently (0.01-2.5) decreased the induction by fluoxetine of serotonin levels yet potentiated (three-fold) its elevation of dopamine and noradrenaline levels. The serotonin(1A) agonist, 8-hydroxy-2-(di-n-propylamino)-tetralin (0.16), mimicked the action of buspirone in reducing resting levels of serotonin (- 60%) and in enhancing those of dopamine (+ 135%) and noradrenaline (+ 165%). Like buspirone, it attenuated the influence of fluoxetine upon serotonin levels, yet facilitated its influence upon dopamine and noradrenaline levels. In contrast, WAY 100,635 selectively potentiated the increase in levels of serotonin (two-fold) versus dopamine and noradrenaline elicited by fluoxetine. Further, WAY 100,635 abolished the inhibitory influence of buspirone upon fluoxetine-induced serotonin release, but only partly interfered with its potentiation of fluoxetine-induced increases in dopamine and noradrenaline levels. The D-2/D-3 receptor antagonist, raclopride (0.16), increased basal dopamine (+ 60%) levels but little influenced those of serotonin and noradrenaline, and failed to modify the action of fluoxetine. The alpha(2)-adrenergic receptor antagonist, 1-(2-pyrimidinyl-piperazine) (2.5), which did not modify resting levels of serotonin, markedly increased those of dopamine (+ 90%) and noradrenaline (+ 190%) and potentiated (two-fold) the increases in dialysate levels of dopamine, noradrenaline and serotonin provoked by fluoxetine. Further, the alpha(2)-adrenergic receptor agonist, S18616, attenuated the enhancement by buspirone of the fluoxetine-induced increase in levels of dopamine and noradrenaline. In conclusion, the inhibitory influence of buspirone upon resting and fluoxetine-stimulated serotonin levels reflects its agonist properties at serotonin(1A) autoreceptors. The facilitatory influence of buspirone upon resting and fluoxetine-stimulated dopamine and noradrenaline levels may also involve its serotonin(1A) properties. However, its principal mechanism of action in this respect is probably the alpha(2)-adrenergic antagonist properties of its metabolite, 1 -(2-pyrimidinyl-piperazine). The present observations are of significance to experimental and clinical studies of the influence of buspirone upon depressive states, alone and in association with antidepressant agents. (C) 1999 IBRO. Published by Elsevier Science Ltd.